23.03MMarket Cap-1.08P/E (TTM)
4.880High4.711Low6.33KVolume4.800Open4.910Pre Close30.07KTurnover0.19%Turnover RatioLossP/E (Static)4.89MShares16.80052wk High1.72P/B15.83MFloat Cap2.07052wk Low--Dividend TTM3.36MShs Float65.550Historical High--Div YieldTTM3.45%Amplitude2.070Historical Low4.749Avg Price1Lot Size
Mangoceuticals Stock Forum
Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
Thursday, 20th February at 7:00 am
Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products via a secure telemedicine platform under the brand MangoRx, proudly annou...
Mangoceuticals Announces the Launch of “Peachesrx” - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
Revolutionary Water-Based Solution Shows Promise in Fighting Bird Flu Crisis - Phase I Results Reveal Major Breakthrough
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow...
Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
Thursday, 6th February at 7:00 am
Dallas, Texas, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products and services via a secure telemedic...
Major H1N1 Treatment Success: Mangoceuticals' Novel Antiviral Shows Promise Against Bird Flu
Benzinga· 1 min ago
No comment yet